To fill this knowledge gap, we analyzed ER expression status in serous ovarian tumors, including LGSOCs, SBTs, and serous cystadenomas (SCAs); the relationship between ER status and oncogenic mutation status; and efficacy of ER inhibition, using MPSC1 cells obtained from LGSOCs. This evidence concerns the gene ESR1 and serous cystadenoma.